AbbVie (ABBV) stock price has done well this year as it surged to a record high of $200. It has jumped by more than 32% this year, outperforming the S&P 500 and Nasdaq 100 indices.

AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

ABBV Quantitative Stock Analysis May 20, 2025 — 09:06 am EDT. ... Detailed Analysis of ABBVIE INC. ABBV Guru Analysis. ABBV Fundamental Analysis. More Information on Pim van Vliet.

The stock's fall snapped a three-day winning streak.

Dividend investing, like most things in life, can be rewarding if done correctly or a headache if you make crucial mistakes. The key to dividend investing is to pick the right typ ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

For this analysis, we will use AbbVie’s stock price $117.93 (8/19/21 close). Analysts are projecting forward EPS of $12.65 per share. The company’s annual dividend is $5.20 per share.

Read why ABBV stock is a hold. Skip to content. ... together with the state of the stock price based on the technical analysis. Although I find AbbVie to be a very strong business that will not ...

AbbVie releases interim analysis on atogepant, an oral migraine prevention drug. Key findings show significant reductions in migraine days and consistent safety profile. Atogepant, known as ...

AbbVie Inc ABBV released on Saturday the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere ... ABBV Price Action: AbbVie stock is up 1.63% at $212.23 at publication Monday.